Obagi Medical Products, Inc. (Nasdaq: OMPI), a leader in topical aesthetic and therapeutic skin health systems, announced today it is presenting two posters highlighting its ELASTIderm? technology at the 65th Annual Meeting of the American Academy of Dermatology (AAD) to be held February 2 ? 6, in Washington, D.C.

The two Obagi-sponsored posters that study the effects of ELASTIderm are:

1. Clinical Evaluation of the Effect of a Novel Bi-Mineral Complex on Periorbital Skin

2. Evaluation of the Effect of a Novel Bi-Mineral Complex on Photoexposed Periorbital Skin

These posters support the ability of ELASTIderm to help the body's natural ability to increase levels of elastin and collagen, and thereby improve elasticity, moisturization and hyperkinetic lines (crow's feet) in periorbital skin. In a regimen of two daily applications, the presence of dermal elastin in skin increased over a six-week period, and statistically significant improvements in measured skin elasticity were seen after only two weeks of use.

ELASTIderm Eye Cream is a novel eye therapy product designed to help the natural abilities of the skin to produce insoluble elastin, decrease the number of wrinkles and increase functional elasticity of the skin.

ELASTIderm contains a novel mineral complex known as copper zinc malonate. According to Dr. Stacy Smith, President, Therapeutics Clinical Research, who was involved in conducting one of the studies, ?Together, these studies showed statistically significant improvement in the periorbital elasticity and appearance of the women, ages 45 to 69, who used ELASTIderm System twice daily in the studies. This may be the first topical treatment that demonstrates such improvements in functional elastin. Our patients who participated in the study remain enthusiastic about their results and continue to request the product.?

Steve Carlson, President and CEO of Obagi Medical Products, said, ?ELASTIderm addresses the $85 million segment of the $800 million facial care market. Importantly, we expect that this innovation in skin care will be well received by dermatologists and their patients.?

Posters will be presented in Hall C at the Washington Convention Center, and will be available for viewing by meeting attendees beginning at 1:00 p.m. on Friday, February 2. Poster presenters will be available at even-number poster displays from 12:00 p.m. to 2:00 p.m. on Saturday, February 3, and at odd-numbered poster displays from 12:00 p.m. to 2:00 p.m. on Sunday, February 4.

The ELASTIderm System was officially launched during AAD and will be available through dispensing physicians throughout the United States later this month.

About Obagi Medical Products, Inc. (www.obagi.com)

Obagi Medical Products is a specialty pharmaceutical company focused on the aesthetic and therapeutic skin health markets. The company develops and commercializes prescription-based, topical skin health systems that enable physicians to treat a range of skin conditions, including pre-mature aging, photodamage, hyperpigmentation (irregular or patchy discoloration of the skin), acne and soft tissue deficits, such as fine lines and wrinkles. Obagi markets and sells physician-dispensed skin care systems directly to plastic surgeons, dermatologists and other physicians who are focused on aesthetic and therapeutic skin care. Obagi products are dispensed throughout the United States and in more than 35 other countries.

Forward-Looking Statements

There are forward-looking statements contained herein, which can be identified by the use of forward-looking terminology such as the words "believes," "expects," "may," "will," "should", "potential," "anticipates," "plans" or "intends" and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from the future results, events or developments indicated in such forward-looking statements. Such factors include, but are not limited to the intense competition our products face and will face in the future, the level of market acceptance of our products, the possibility that our products could be rendered obsolete by technological or medical advances and the possibility that our products may cause undesirable side effects. A more detailed discussion of these and other factors that could affect results is contained in our filings with the U.S. Securities and Exchange Commission, including our Registration Statement on Form S-1. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. No assurance can be given that the future results covered by the forward-looking statements will be achieved. All information in this press release is as of the date of this press release and Obagi Medical Products does not intend to update this information.